Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial

(2019) Michael P Whyte et al.   Lancet Diabetes & Endocrinology

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

(2019) Erik A Imel et al.   LANCET

Burosumab: First Global Approval

(2018) Yvette N. Lamb   DRUGS

Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale

(2018) Michael P Whyte et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Burosumab Therapy in Children with X-Linked Hypophosphatemia

(2018) Thomas O. Carpenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Craniosynostosis as the Presenting Feature of X-linked Hypophosphatemic Rickets

(2018) Janaki D. Vakharia et al.   PEDIATRICS

Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications

(2015) Silje Rafaelsen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23

(2015) Erik A. Imel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

(2014) Agnès Linglart et al.   Endocrine Connections

A clinician's guide to X-linked hypophosphatemia

(2011) Thomas O Carpenter et al.   JOURNAL OF BONE AND MINERAL RESEARCH